Search results for "ALPHA"

showing 10 items of 3228 documents

Clinical evaluation of pancreatitis-associated protein as a serum marker of hepatocellular carcinoma: Comparison with α-fetoprotein

1998

This study evaluated the significance of serum pancreatitis-associated protein (PAP) assay, as a marker of hepatocellular carcinoma (HCC), in comparison and combined with α-fetoprotein (AFP) assay. Sixty-five patients with HCC, 59 with liver cirrhosis (LC) and 68 asymptomatic controls (C) were studied. PAP and AFP values significantly increased from C to LC and HCC group (p < 0.0001). The area under receiver-operating characteristic (ROC) curve for the two markers was not statistically different. At 100% specificity, ROC analysis gave a cut-off level for AFP of 166 IU/l with 40% sensitivity, and a cut-off level of 240 µg/l for PAP with 23% sensitivity. Diagnostic accuracy of combined AFP…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyCirrhosisCarcinoma HepatocellularPancreatitis-Associated ProteinsAsymptomaticSensitivity and SpecificityAntigens NeoplasmBiomarkers TumorMedicineHumansLectins C-TypeneoplasmsTumor markerAgedbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasedigestive system diseasesLogistic ModelsOncologyHepatocellular carcinomaPancreatitisFemalealpha-Fetoproteinsmedicine.symptombusinessClinical evaluationSerum markersAcute-Phase Proteins
researchProduct

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

2003

We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive imatinib (n=69) or interferon (IFN)/Ara-C (n=70). The response was sequentially monitored by cytogenetics from bone marrow metaphases (n=803) and qualitative and quantitative RT-PCR from peripheral blood samples (n=1117). Complete cytogenetic response (CCR) was achieved in 60 (imatinib, 87%) vs 10 patients (IFN/Ara-C, 14%) after a median observation time of 24 months. Within the first year after CCR, best median ratio BCR-ABL/ABL was 0.087%, (imatinib, n=48) vs 0.27% (IFN/Ara-C, n=9, P=0.025). BCR-ABL was undetectable in 25 c…

AdultMaleCancer Researchmedicine.medical_specialtyAntimetabolites AntineoplasticFusion Proteins bcr-ablAlpha interferonAntineoplastic AgentsBiologyGastroenterologyPiperazinesCytogeneticsRecurrenceRisk Factorshemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProspective StudiesRNA MessengerneoplasmsInterferon alfaAgedHematologyABLCross-Over Studiesbreakpoint cluster regionCytarabineInterferon-alphaImatinibHematologyMiddle Agedmedicine.diseasePrognosisPyrimidinesTreatment OutcomeOncologyImmunologyBenzamidesCytarabineImatinib MesylateFemaleChronic myelogenous leukemiamedicine.drugLeukemia
researchProduct

Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside

1993

Abstract Patients with Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) and on interferon (IFN)-α-2c treatment for at least two months were entered in the present pilot study. IFN-α treatment was maintained identically and cytosine arabinoside (Ara-C) was added at monthly cycles of 10 mg/m 2 /day for ten days subcutaneously. In the case of a leukocyte nadir above 10 G/1, the Ara-C dose was increased to 20 mg/m 2 /day for 10 days per month. Ten of the eleven patients entered in this study were evaluable for toxicity and response. They received a total of 87 IFN-α/Ara-C cycles (3–14/patient). Five patients received 1–5 cycles with Ara-C dose intensification to 20 mg/m …

AdultMaleCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentAlpha interferonGastroenterologyDrug Administration ScheduleLeukocyte CountLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicinemedicineHumansInterferon alfaAgedChemotherapybusiness.industryCytarabineHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyRecombinant ProteinsSurgeryDiarrheaOncologyInterferon Type IToxicityCytarabineFemalemedicine.symptombusinessmedicine.drugChronic myelogenous leukemiaLeukemia Research
researchProduct

Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.

1995

Interferon alpha-2a (IFN-alpha) and folinic acid (FA) have been shown to modulate the cytotoxic effects of 5-fluorouracil (5-FU) in the treatment of cancer. A phase II study was initiated to evaluate the effect of a combination of 5-FU/FA/IFN-alpha in patients with advanced pancreatic cancer. Sixty previously untreated patients with advanced adenocarcinoma of the pancreas were treated with 500 mg m-2 FU via an intravenous bolus 1 h after the initiation of a 2 h infusion of 500 mg m-2 FA. Before starting the FA infusion, 6 million units (MU) of IFN-alpha was administered subcutaneously. The treatment was repeated once a week. Of 57 evaluable patients, eight (14%) had a partial response (PR),…

AdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentLeucovorinAlpha interferonAdenocarcinomaInterferon alpha-2GastroenterologyFolinic acidInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInterferon alfaAgedChemotherapybusiness.industryInterferon-alphaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryPancreatic NeoplasmsOncologyFluorouracilFemaleFluorouracilbusinessProgressive diseasemedicine.drugResearch ArticleBritish Journal of Cancer
researchProduct

Anterior limbic alpha-like activity: a low resolution electromagnetic tomography study with lorazepam challenge

2005

Summary Objective To verify findings of an independently regulated anterior limbic alpha band source. Methods In a randomised cross-over study, the spontaneous EEG was recorded in nine healthy subjects after i.v. lorazepam or placebo. Intracerebral current densities within classical frequency bands were estimated with low resolution electromagnetic tomography [LORETA] and compared between groups with t -statistical parametric mapping [SPM{ t }]. A region-of-interest [ROI] based method was used to compare frontal and occipital alpha band activity changes. Results Irrespective of treatment group, local maxima of alpha band power were localised both in the occipital lobe, Brodman area [BA] 18,…

AdultMaleCingulate cortexFrequency bandAlpha (ethology)ElectroencephalographyLorazepamStatistical parametric mappingStatistics NonparametricElectromagnetic FieldsNuclear magnetic resonanceLimbic systemPhysiology (medical)mental disordersLimbic SystemmedicineHumansSingle-Blind MethodAnterior cingulate cortexPhysicsCross-Over Studiesmedicine.diagnostic_testSensory SystemsAlpha Rhythmmedicine.anatomical_structureNeurologyInjections IntravenousNeurology (clinical)Occipital lobeNeuroscienceClinical Neurophysiology
researchProduct

Serum levels of cytokines in chronic liver diseases

1992

Serum levels of interleukin-1 (IL-1 beta), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), and C-reactive protein (CRP) were investigated in patients with chronic liver diseases (CLD) and correlated with the type of underlying disease and various clinical and laboratory parameters. Two hundred sixty-four patients suffering from various CLD were studied; 136 cases presented with liver cirrhosis, and 128 patients were in the noncirrhotic stage of their underlying liver diseases. Serum levels of IL-1 beta, IL-6, TNF-alpha, IFN-gamma, and CRP were elevated in patients with CLD. Endogenous cytokine patterns in CLD were stage dependent and only margina…

AdultMaleCirrhosisAdolescentmedicine.medical_treatmentDiseaseReference ValuesHumansMedicineInterferon gammaChildBeta (finance)Hepatologybiologybusiness.industryLiver DiseasesC-reactive proteinGastroenterologyMiddle Agedmedicine.diseasePathophysiologyC-Reactive ProteinCytokineChronic DiseaseImmunologybiology.proteinCytokinesFemaleTumor necrosis factor alphabusinessmedicine.drugGastroenterology
researchProduct

Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induct…

2002

High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic hepatitis C were randomised to receive, after 4 weeks of 10 mU daily of alpha-interferon (induction), 3 mU daily for 22 weeks and 3 mU thrice weekly for 26 weeks of either interferon alone (monotherapy) or interferon plus 1000-1200 mg daily of ribavirin (combination therapy). At the end of the induction phase, 23 (56%) subjects had cleared HCV-RNA. During therapy, breakthrough w…

AdultMaleCombination therapyAdolescentHepacivirusAlpha interferonViremiaEnzyme-Linked Immunosorbent AssayHepacivirusPharmacologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialInterferonlawVirologyRibavirinHumansMedicineViremiaAgedAntiviral AgentHepatologybiologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseInfectious DiseasesTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalebusinessmedicine.drugHuman
researchProduct

Sensor acceptance model:measuring patient acceptance of wearable sensors

2008

Summary Objectives: This project focuses on how patients respond to wearable biomedical sensors, since patient acceptance of this type of monitoring technology is essential for enhancing the quality of the data being measured. There is a lack of validated questionnaires measuring patient acceptance of telemedical solutions, and little information is known of how patients evaluate the use of wearable sensors. Methods: In information systems research, surveys are commonly used to evaluate the user satisfaction of software programs. Based on this tradition and adding measures of patient satisfaction and health-related quality of life (HRQoL), a Sensor Acceptance Model is developed. The model i…

AdultMaleComputer sciencemedia_common.quotation_subjectHealth BehaviorWearable computerPilot ProjectsHealth InformaticsElectrocardiographyPatient satisfactionQuality of life (healthcare)Health Information ManagementCronbach's alphaHuman–computer interactionSurveys and QuestionnairesInformation systemHumansQuality (business)SimulationMonitoring Physiologicmedia_commonAdvanced and Specialized NursingConstruct validityMiddle AgedPatient Acceptance of Health CareConfirmatory factor analysisPatient SatisfactionHealth Care SurveysQuality of LifeFemaleErgonomicsAttitude to HealthInformation Systems
researchProduct

Types of Triggers in Migraine - Factor Structure of the Headache Triggers Sensitivity and Avoidance Questionnaire and Development of a New Short Form…

2020

OBJECTIVE: To examine the factor structure of the Headache Triggers Sensitivity and Avoidance Questionnaire (HTSAQ) and its German version (HTSAQ-G), in order to identify potential different types of triggers. Furthermore, a short form of the questionnaire was developed. BACKGROUND: The HTSAQ includes 24 of the most commonly reported headache triggers (eg, stress, odors, lack of sleep). Both the HTSAQ and HTSAQ-G appeared to be reliable and valid measures of sensitivity to and avoidance of headache triggers. METHODS: In a cross-country collaboration, data from 2 cross-sectional studies including N = 391 individuals diagnosed with migraine from Australia (n = 222) and Germany (n = 169) were …

AdultMaleCoping (psychology)AdolescentPsychometricsMigraine DisordersFactor structure03 medical and health sciencesYoung Adult0302 clinical medicineChronic MigraineCronbach's alphaGermanymedicineHumans030212 general & internal medicineAgedAged 80 and overbusiness.industryCluster headacheAustraliaMiddle Agedmedicine.diseaseConfirmatory factor analysisClinical PracticeCross-Sectional StudiesNeurologyMigraineFemaleNeurology (clinical)businessFactor Analysis Statistical030217 neurology & neurosurgeryClinical psychologyHeadacheReferences
researchProduct

Development and Validation of the AdT-Physio Scale: A Tool to Assess Adherence and Perception of Physical Therapist Intervention in Patients With Cys…

2019

Abstract Objective The purpose of this study was to develop a scale to measure patient adherence to physical therapist intervention and to report psychometric properties in patients with cystic fibrosis (CF). Methods This observational, multicenter, qualitative, and cross-sectional study was divided into 2 phases: development of scale items (content validity) and assessment of psychometric properties (construct validity, reliability, and convergent/discriminant validity). Recruited were 121 patients with CF (aged ≥16 years). Sociodemographic characteristics, lung function testing, Coping with Stress Self-Efficacy, brief Coping Orientation to Problems Experienced inventory, and the scale of …

AdultMaleCoping (psychology)Cystic FibrosisPatientsPsychometricsPhysical Therapy Sports Therapy and RehabilitationCorrelation03 medical and health sciences0302 clinical medicineCronbach's alphaSurveys and QuestionnairesAdaptation PsychologicalContent validityMedicineHumans030212 general & internal medicinePhysical Therapy Modalitiesbusiness.industryDiscriminant validityConstruct validityReproducibility of ResultsConfirmatory factor analysisPhysical TherapistsCross-Sectional Studies030228 respiratory systemPatient ComplianceObservational studyFemalePerceptionbusinessClinical psychologyPhysical therapy
researchProduct